Keynote: Antibody drug conjugates for cancer therapy: where we are and what lies ahead?

• In the last year, four ADCs have been approved for cancer therapy, and many others are in advanced-stage clinical trials
• Advancements have been made in several aspects of the underlying technology including targets, drugs, linkers, and conjugation technologies
• An overview of the field will be provided and the challenges that lie ahead will be discussed

Peter Senter, VP, Distinguished Research Fellow, Seattle Genetics